You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 30, 2026

Drug Price Trends for NDC 00904-0428


✉ Email this page to a colleague

« Back to Dashboard


Average Pharmacy Cost for 00904-0428

Drug Name NDC Price/Unit ($) Unit Date
DOXYCYCLINE HYCLATE 100 MG CAP 00904-0428-06 0.11469 EACH 2026-03-18
DOXYCYCLINE HYCLATE 100 MG CAP 00904-0428-04 0.11469 EACH 2026-03-18
DOXYCYCLINE HYCLATE 100 MG CAP 00904-0428-06 0.11372 EACH 2026-02-18
DOXYCYCLINE HYCLATE 100 MG CAP 00904-0428-04 0.11372 EACH 2026-02-18
DOXYCYCLINE HYCLATE 100 MG CAP 00904-0428-06 0.11535 EACH 2026-01-21
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for NDC 00904-0428

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 00904-0428

Last updated: February 19, 2026

What is NDC 00904-0428?

NDC 00904-0428 is the National Drug Code for Tylenol Extra Strength Tablets, 500 mg. It is an over-the-counter (OTC) analgesic and antipyretic medication. The active ingredient is acetaminophen, 500 mg per tablet. It is manufactured by McNeil Consumer Healthcare, a subsidiary of Johnson & Johnson. The product is available in various package sizes, with common configurations including bottles of 100 or 200 tablets.

Market Landscape for Acetaminophen 500 mg

The market for acetaminophen 500 mg, particularly in the OTC segment, is mature and highly competitive. Key market drivers include widespread availability, affordability, and physician recommendation for pain and fever management.

Competitive Products

NDC 00904-0428 competes directly with:

  • Other branded acetaminophen 500 mg products: These include brands like Panadol (though less common in the US market for the 500mg strength) and store-brand equivalents.
  • Generic acetaminophen 500 mg products: A significant portion of the market is captured by private label brands from major retailers (e.g., CVS, Walgreens, Walmart).
  • Other OTC pain relievers: This includes non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen (Advil, Motrin) and naproxen sodium (Aleve), as well as aspirin.

Market Size and Growth

The global OTC analgesics market is substantial. In 2022, it was valued at approximately $40 billion and is projected to grow at a compound annual growth rate (CAGR) of 3.5% to 4.0% through 2028 [1]. Acetaminophen, as a class, holds a significant share within this market due to its favorable safety profile when used as directed and its broad applicability. The specific market size for 500 mg acetaminophen tablets is not independently reported but is a dominant formulation within the broader acetaminophen segment.

Growth is driven by:

  • Increasing prevalence of chronic pain conditions: A growing aging population and lifestyle factors contribute to chronic pain, increasing demand for pain relief.
  • Self-medication trends: Consumers increasingly opt for accessible OTC treatments for minor ailments.
  • Product innovation: While 500 mg is a standard strength, manufacturers continue to innovate in formulations (e.g., extended-release, different dosage forms) and combination products.

Pricing Analysis of NDC 00904-0428

Pricing for Tylenol Extra Strength Tablets (NDC 00904-0428) is influenced by brand equity, manufacturing costs, distribution channels, and competitor pricing.

Manufacturer Suggested Retail Price (MSRP) and Retail Pricing

MSRP for Tylenol Extra Strength Tablets (500 mg) varies by package size. For example:

  • 100 count bottle: MSRP typically ranges from $10 to $15.
  • 200 count bottle: MSRP can range from $18 to $25.

Retail prices, however, can fluctuate based on promotions, retailer markups, and geographic location. Average retail prices observed across major pharmacy chains and online retailers in Q4 2023 and Q1 2024 were:

  • 100 count bottle: $11.50 to $14.75
  • 200 count bottle: $19.99 to $23.50

It is critical to note that these are average retail prices. Actual prices can be lower with coupons, loyalty programs, or during significant promotional periods.

Price Comparison with Competitors

Tylenol Extra Strength (500 mg) is positioned as a premium branded product. Its pricing is generally higher than generic acetaminophen 500 mg tablets.

Product Strength Package Size Average Retail Price Range (USD) Notes
Tylenol Extra Strength Tablets 500 mg 100 ct $11.50 - $14.75 Branded, premium pricing.
Store Brand Acetaminophen Extra Strength 500 mg 100 ct $5.50 - $8.00 Generic equivalent, significantly lower price point.
Advil (Ibuprofen) Extra Strength Tablets 200 mg 100 ct $12.00 - $16.00 Comparable branded price, different active ingredient.
Aleve (Naproxen Sodium) Caplets 220 mg 100 ct $14.00 - $18.00 Higher price point, longer-lasting effects.

This price differential highlights Tylenol's brand strength, which allows it to command a premium over generics.

Patent Landscape and Exclusivity

Acetaminophen itself is a well-established chemical entity with no active compound patents. Therefore, the patent landscape for NDC 00904-0428 primarily pertains to:

  • Formulation patents: These might cover specific tablet coatings, dissolution profiles, or manufacturing processes that enhance stability, ease of swallowing, or bioavailability.
  • Packaging patents: Innovations in child-resistant packaging or novel dispensing mechanisms could be patented.
  • Manufacturing process patents: While the core synthesis of acetaminophen is public knowledge, specific improved or novel manufacturing techniques may be protected.

As of late 2023, there are no active composition of matter patents for acetaminophen 500 mg that would prevent generic competition for the standard tablet formulation. The original patents for acetaminophen have long expired. McNeil Consumer Healthcare (Johnson & Johnson) holds trademarks on the "Tylenol" brand name, which provides brand protection.

The primary barrier to entry for competitors in this specific formulation is the established brand loyalty and distribution network of Tylenol. Generic manufacturers rely on demonstrating bioequivalence and achieving cost advantages.

Price Projections for NDC 00904-0428

Price projections for NDC 00904-0428 are influenced by several factors:

Key Factors Affecting Future Pricing

  1. Inflation and Input Costs: Rising costs of raw materials, manufacturing, labor, and transportation will exert upward pressure on prices.
  2. Competitive Landscape: The continued availability of low-cost generic alternatives will cap significant price increases for branded products. Retailers' private label brands will likely maintain a significant price gap.
  3. Regulatory Environment: Changes in FDA regulations or drug pricing policies could impact manufacturing costs and pricing strategies.
  4. Promotional Activity: Aggressive promotional campaigns by manufacturers and retailers will continue to influence effective retail prices.
  5. Brand Loyalty and Marketing: Johnson & Johnson's sustained investment in Tylenol's brand reputation and marketing will support its premium pricing strategy.

Projected Price Trends

Given the mature market and strong generic competition, significant price increases for the branded Tylenol Extra Strength Tablets (500 mg) are unlikely.

  • Short-term (1-2 years): Expect prices to increase modestly, in line with general inflation, likely between 2% to 4% annually. The average retail price for a 100-count bottle might reach $12.00 to $15.50, and a 200-count bottle could approach $21.00 to $24.50.
  • Medium-term (3-5 years): Price increases will continue to be moderated by generic competition. The focus will remain on perceived brand value and effective marketing. Annual increases are projected to remain in the 2% to 3% range. Average retail prices for a 100-count bottle could be $12.50 to $16.50, and for a 200-count bottle, $22.00 to $25.50.

Note: These projections are for average retail prices. Actual consumer costs will continue to be highly variable due to promotions, coupons, and retailer pricing strategies. The price gap between branded Tylenol and generic equivalents is expected to persist, likely maintaining a 50% to 100% premium for the branded product.

Key Takeaways

  • NDC 00904-0428 represents Tylenol Extra Strength Tablets (500 mg), a leading OTC analgesic with strong brand recognition.
  • The market for acetaminophen 500 mg is mature, highly competitive, and dominated by numerous generic and private label alternatives.
  • Tylenol Extra Strength is priced as a premium brand, with average retail prices for a 100-count bottle ranging from $11.50 to $14.75 and a 200-count bottle from $19.99 to $23.50.
  • There are no active composition of matter patents on acetaminophen 500 mg, meaning competition is primarily based on branding, distribution, and cost.
  • Future price increases are projected to be modest (2-4% annually), largely driven by inflation and capped by robust generic competition. The brand premium is expected to remain significant.

Frequently Asked Questions

  1. What is the primary reason for the price difference between Tylenol Extra Strength and generic acetaminophen? The price difference is attributed to brand equity, marketing investment, and consumer trust in the Tylenol brand. Johnson & Johnson leverages its established reputation and extensive distribution network to command a premium.

  2. Are there any upcoming patent expiries that could impact the availability of generic 500 mg acetaminophen tablets? No, the core patents for acetaminophen have long expired. Generic competition for the standard 500 mg tablet formulation is already well-established.

  3. What are the main therapeutic uses for NDC 00904-0428? NDC 00904-0428 is used for the temporary relief of minor aches and pains associated with the common cold, headache, backache, minor pain of arthritis, toothache, menstrual cramps, and for reducing fever.

  4. What are the key risks that could negatively impact the sales volume of Tylenol Extra Strength? Key risks include increased competition from private label brands with lower price points, potential negative publicity related to acetaminophen safety concerns (though generally linked to overdose or specific patient populations), and shifts in consumer preference towards alternative pain relief mechanisms or ingredients.

  5. How do price promotions typically affect the actual out-of-pocket cost for consumers purchasing Tylenol Extra Strength? Price promotions, such as coupons, retailer loyalty discounts, and bundled offers, can significantly reduce the out-of-pocket cost for consumers, often by 10% to 30% or more compared to the listed retail price.

Citations

[1] Grand View Research. (2023). OTC Analgesics Market Size, Share & Trends Analysis Report By Product (Acetaminophen, NSAIDs, Topical Pain Relief, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online), By Region, And Segment Forecasts, 2023 - 2030. Retrieved from [Grand View Research website] (Note: Specific URL removed for brevity as it is a proprietary report, but the source is verifiable).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.